{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T23:24:18Z","timestamp":1770506658865,"version":"3.49.0"},"reference-count":13,"publisher":"Wiley","issue":"5P2","license":[{"start":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:00:00Z","timestamp":1325808000000},"content-version":"vor","delay-in-days":615,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2010,5]]},"abstract":"<jats:p>Understanding and appreciating the science of pharmacoeconomics have become even more important for health care providers and insurers during the recent economic downturn. Evaluating the true costs of any disease is complex; both direct costs, such as costs of drug therapy and the provision of care, and indirect costs, such as lost earnings and reduced quality of life, must be taken into account. With chronic liver disease, the most recent data indicate that direct costs were more than $2 billion whereas indirect costs were more than $450 million. Hepatic encephalopathy, a common complication of chronic liver disease, contributes to this economic burden. Although patients' length of stay during hospitalization for hepatic encephalopathy decreased from almost 9 days to 6 days (and has remained stable over the past few years) from 1993 to 2007, hospitalization costs rose from $13,000 to $30,000\/hospital stay. In addition, 22% of patients were discharged directly to nursing homes or rehabilitation centers, which increases total costs. When assessing therapy for hepatic encephalopathy, it is important to consider the total costs of the disease, not just treatment costs. Although more expensive on a daily basis than lactulose, rifaximin has been shown to reduce hospitalization rates, has a better adverse\u2010effect profile, and increases patient compliance. One study found that rifaximin produced a cost savings\/patient\/year of more than $3000 over lactulose therapy.<\/jats:p>","DOI":"10.1592\/phco.30.pt2.28s","type":"journal-article","created":{"date-parts":[[2010,4,23]],"date-time":"2010-04-23T07:22:33Z","timestamp":1272007353000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Pharmacoeconomics of Hepatic Encephalopathy"],"prefix":"10.1002","volume":"30","author":[{"given":"Guy","family":"Neff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,6]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1586\/17474124.2.6.785"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1746-6342.2006.03215.x"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcg110"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(99)80144-5"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21515"},{"key":"e_1_2_1_7_2","unstructured":"American Gastroenterological Association.The burden of gastrointestinal diseases 2001. Available fromwww.gastro.orgclinicalResburdenReport.htmlAccessedDecember 3 2009."},{"issue":"4","key":"e_1_2_1_8_2","first-page":"390A","article-title":"Projecting the future healthcare burden from hepatitis C in the United States","volume":"28","author":"Davis GL","year":"1998","journal-title":"Hepatology"},{"key":"e_1_2_1_9_2","unstructured":"Agency for Healthcare Research and Quality.HCUPnet healthcare cost and utilization project. Available fromwww.hcupnet.ahrq.govAccessedMay 14 2009."},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2006.10.107"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-006-9442-4"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03464.x"},{"key":"e_1_2_1_13_2","unstructured":"MantryPS MunsafS.Analysis of the effect of rifaximin plus lactulose on hospitalizations in patients with end\u2010stage liver disease.Poster presented at the 59th annual meeting of the American Association for the Study of Liver Diseases San Francisco CA October 31\u2010November 4 2008."},{"key":"e_1_2_1_14_2","doi-asserted-by":"crossref","unstructured":"NeffG. LeevyC. FrederickT. et al.Rifaximin reduces the risk of hospitalizations in patients with previous episodes of hepatic encephalopathy: results from a phase 3 placebo\u2010controlled trial.Presented at digestive disease week Chicago IL May 31 2009.","DOI":"10.1016\/S0016-5085(09)60056-1"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.30.pt2.28S","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.30.pt2.28S","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T09:47:37Z","timestamp":1761040057000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.30.pt2.28S"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":13,"journal-issue":{"issue":"5P2","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["10.1592\/phco.30.pt2.28S"],"URL":"https:\/\/doi.org\/10.1592\/phco.30.pt2.28s","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5]]},"assertion":[{"value":"2012-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}